Communiqués Plus Therapeutics, Inc.

Actions

PSTV

US72941H5090

Temps Différé Nasdaq Autres places de cotation 16:22:32 28/06/2024			Varia. 5j.	Varia. 1 janv.
1,429 ^USD	-2,12%		-18,78%	-16,46%

07/06	Plus Therapeutics, Inc. reçoit la démission du Dr Norman Lafrance, son médecin-chef, à compter du 12 juin 2024	CI
07/06	Plus Therapeutics va recevoir une avance de 3,3 millions de dollars du CPRIT pour un programme de développement radiothérapeutique	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases Phase 1 Dose Escalation Trial: Update for Initial Safety, Feasibility and Preliminary Efficacy	11/06	PU
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT	07/06	AQ
Plus Therapeutics Announces New Employment Inducement Grants	17/05	AQ
Plus: Q1 Earnings Snapshot	15/05	AQ
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	15/05	AQ
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024	13/05	AQ
Plus Therapeutics : Material Agreement - Form 8-K	10/05	PU
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial	09/05	AQ
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial	08/05	AQ
Plus Therapeutics : The use of CNSide in Clinical Management of LMD	08/05	PU
Plus Therapeutics Announces Private Placement Financing of up to $18 Million	06/05	AQ
Plus Therapeutics : Nuclear Medicine and Neurooncology (NMN) Symposium 2024	29/04	PU
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense	22/04	AQ
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team	09/04	AQ
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference	27/03	AQ
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic	25/03	AQ
Plus Therapeutics : March 2024 Corporate Presentation	13/03	PU
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases	11/03	AQ
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	05/03	AQ
Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024	27/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Plus Therapeutics, Inc.

Actions

PSTV

US72941H5090

Communiqués

Filtres